References 2

1. Alan M. Krensky; William M. Bennett; Flavio Vincenti. Immunosuppressants,

Tolerogens, and Immunostimulants. In: Burton LL, Lazo JS, Parker KL (eds),

Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edn.

New York. McGraw-Hill, 2006 [26].

2. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.

3. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller CS

(eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.

Ontario, BC Decker, 2002 [17].

4. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.

Synergistic enhancement of cell-mediated immunity by interleukin-12 plus

interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest

Dermatol. 2002 Feb; 118(2):366-71.

5. Katzung BG. Immunomodulating Agents. In: Basic and Clinical Pharmacology

9th Edition. New YorkMcGraw-Hill, 2007 [56].

6. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology in

General Medicine, 7th Edition, 2008 [27].

7. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-413.

8. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic and

clinical immunology 6th ed p. 1-14.

9. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.

10.Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34

11. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK, Nelson F,

Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of Disease 6 th

Edition. Philadelphia, Saunders Elsevier 2006 [6].

12.Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].

13.Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System. In: A

Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007, p.1-

49.

14.Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial Series:

Rapid Learning Inc:RapidLearningCenter.com.

15.Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:

Immunology 6th Edn, London, Mosby 2001. P297 - 301.

16.Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN, and

Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in

activated T lymphocytes

17.Heiserman DL. Immune Response. In: Introduction to Immunology.

SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech

/immunology.

18.Ananthnarayan and Panicker. Structure and Functions of the Immune System.

In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan, 2005 [15].

19.Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical

Medicine 8th Edn. Elsevier 2008.

20. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy, Immunosuppressants

and Immunostimulants. In. Pharmacology and Pharmacotherapeutics, 22nd

Edn. Mumbai Popular Prakashan, 2009 [77].

21.Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology. London,

Mosby Elsevier, 2007 [5].

22.Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's Pharmacology

Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant drugs. Churchill

Livingstone, Elsevier 2011.

23. Scribed

24.Kat

25.Kat

26.Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen planus.

British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.

27.Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen Planus – A

Review. Indian Journal Of Applied Research. March 2013, Vol 3, Issue 3. p289-

290.

28.Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds) Clinical and

Basic Immunodermatology. Springer, 05-Nov-2008 [32].

29.Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation and

Management. J. C. D. 68:494-9.

30.Gao F. Determination of corticosteroids in human plasma using micromass

LC/MS/MS. Apr 1, 2003.

31.Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition. Florida,

Taylo and Francis 2008. Alphabetical Presentation of Drugs.

32.Shanker

33.L3

34.Aberra NF, Lichtenstein GR. Review Article: Monitoring of Immunomodulators

in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2005; 21(4):307-319.

35.Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in rheumatoid

arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed. 1998; 65:267-

273.

36.Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral Biology and

Medicine 1993; 4(2):141-158.

37.C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the local

application of ciclosporine A on chronic erosive lichen planus of the oral cavity

38.xxx

39.Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study of 570

patients with oral lichen planus: persistence, remission, and malignant

association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.

40.Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J Clin

Case Rep 3: (2013) 285

41.J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.

Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.

1977 March 12; 1(6062): 671–674.

42.Irene

43.Ison

44.James SH and David W. Kimberlin DW. Herpes Simplex Virus in Transplant

Recipients. In: Infectious Disease and Antimicrobial Agents.

www.antimicrobe.org/t02.asp.

45.Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial Virus.

Drugs R D. 2011 September; 11(3): 215–226.

46.Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in

patients with chronic obstructive pulmonary disease in a national cohort is

without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-

84.

48.Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,

Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer

Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,

USA, 2008.

49.Erbitux® (cetuximab) Prescribing Information, ImCloneSystems Incorporated,

New York, NY, USA, 2008.

50.S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head and

neck cancer using tumor antigen-specific monoclonal antibodies,” Current

Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.

51.R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck

cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.

52.National Comprehensive Cancer Network, Head and Neck Cancers: National

Comprehensive Cancer Network Clinical Practice Guidelines in Oncology,

version 2, November 2008, http://www.nccn.org/professionals/physician

gls/PDF/ head-and-neck.pdf.

53.A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck cancer,”

Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.

54.T. L. Whiteside, “Immunobiology and immunotherapy of head and neck

cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.

55.P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV

nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted

cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.

8942-8949, 2005.

56.E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of

human monocyte-derived dendritic cells with native tumor DNA induces

antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,

no. 12, pp. 1624-1631, 2006.

57.National Institutes of Health. ClinicalTrials.gov, November 2008,

http://www.clinicaltrials.gov/ct2/home.

58.J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF, a

second-generation oncolytic herpes simplex virus expressing granulocyte

macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.

22,pp. 6737–6747, 2006.

59.R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of

OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with

newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”

Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.

60.Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the treatment of

solid tumors other than melanoma and renal cell carcinoma,” Anti-Cancer

Drugs, vol.17, no.1, pp.1-12, 2006.

61.B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination nonviral

interleukin-2 gene immunotherapy for head and neck cancer: from bench top

to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.

62.A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with perilymphatic

interleukin 2 in patients with resectable squamous cell carcinoma of the oral

cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97, 2002.

http://www.clinicaltrials.gov/ct2/home

63.W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H. Chang,

“Phase I-II study of advanced head and neck squamous cell carcinoma patients

treated with recombinant human interferon gamma,” Archives of

Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.

64.S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination cisplatin,

5-fluorouracil, and interferon-alpha in the treatment of advanced esophageal

carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.

65.S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive

recombinant interleukin-2 and alpha-interferon therapy in patients with

advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.

2326–2331, 1993.

66.C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral

administration of recombinant human interleukin 12 in head and neck

squamous cell carcinoma patients elicits a T-Helper 1 profile in the

locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–

2635, 2004.

67.J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J. Brandwein,

and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic, induces

maturation and activation of human dendritic cells in vitro,” Journal of

Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.

68.M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53 peptide

presented by HLA-A24 induces cytotoxic T lymphocytes that recognize

squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.

6, no. 3, pp. 979–986, 2000.

69.T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De Leo,

“p53 as an immunotherapeutic target in head and neck cancer,” Advances in

Otorhinolaryngology, vol. 62, pp. 151–160, 2005.

70.Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune

response in patients with primary malignant melanoma of the esophagus after

immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese

Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.

71.M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-cell

responses to human CEA from patients immunized with recombinant avipox-

CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.

47.J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential

vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with

vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-

stimulating factor, in patients with carcinoembryonic antigen-expressing

carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.

Alan M. Krensky; William M. Bennett; Flavio Vincenti. Immunosuppressants,




48.Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.

49.Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller CS



50.Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.



Dermatol. 2002 Feb; 118(2):366-71.

51.Katzung BG. Immunomodulating Agents. In: Basic and Clinical Pharmacology


52.Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology in


53.Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-413.

54.Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic and

clinical immunology 6th ed p. 1-14.

55.Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.

56.Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34

57. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK, Nelson F,

Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of Disease 6 th

Edition. Philadelphia, Saunders Elsevier 2006 [6].

58.Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].

59.Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System. In: A

Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007, p.1-

49.

60.Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial Series:

Rapid Learning Inc:RapidLearningCenter.com.

61.Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:


62.Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN, and

Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in


63.Heiserman DL. Immune Response. In: Introduction to Immunology.


/immunology.

64.Ananthnarayan and Panicker. Structure and Functions of the Immune System.

In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan, 2005 [15].

65.Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical


66. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy, Immunosuppressants

and Immunostimulants. In. Pharmacology and Pharmacotherapeutics, 22nd

Edn. Mumbai Popular Prakashan, 2009 [77].

67.Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology. London,

Mosby Elsevier, 2007 [5].

68.Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's Pharmacology

Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant drugs. Churchill

Livingstone, Elsevier 2011.

69. Scribed

70.Kat

71.Kat

72.Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen planus.

British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.

73.Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen Planus – A

Review. Indian Journal Of Applied Research. March 2013, Vol 3, Issue 3. p289-

290.

74.Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds) Clinical and

Basic Immunodermatology. Springer, 05-Nov-2008 [32].

75.Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation and

Management. J. C. D. 68:494-9.

76.Gao F. Determination of corticosteroids in human plasma using micromass

LC/MS/MS. Apr 1, 2003.

77.Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition. Florida,

Taylo and Francis 2008. Alphabetical Presentation of Drugs.

78.Shanker

79.L3

80.Aberra NF, Lichtenstein GR. Review Article: Monitoring of Immunomodulators

in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2005; 21(4):307-319.

81.Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in rheumatoid

arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed. 1998; 65:267-

273.

82.Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral Biology and

Medicine 1993; 4(2):141-158.

83.C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the local

application of ciclosporine A on chronic erosive lichen planus of the oral cavity

84.xxx

85.Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study of 570

patients with oral lichen planus: persistence, remission, and malignant


86.Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J Clin

Case Rep 3: (2013) 285

87.J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.


1977 March 12; 1(6062): 671–674.

88.Irene

89.Ison

90.James SH and David W. Kimberlin DW. Herpes Simplex Virus in Transplant

Recipients. In: Infectious Disease and Antimicrobial Agents.


91.Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial Virus.

Drugs R D. 2011 September; 11(3): 215–226.

92.Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in



84.




USA, 2008.






75.R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck


76.National Comprehensive Cancer Network, Head and Neck Cancers: National

Comprehensive Cancer Network Clinical Practice Guidelines in Oncology,

version 2, November 2008, http://www.nccn.org/professionals/physician

gls/PDF/ head-and-neck.pdf.

77.A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck cancer,”

Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.

78.T. L. Whiteside, “Immunobiology and immunotherapy of head and neck


79.P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV



8942-8949, 2005.

80.E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of



no. 12, pp. 1624-1631, 2006.

81.National Institutes of Health. ClinicalTrials.gov, November 2008,


82.J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF, a

second-generation oncolytic herpes simplex virus expressing granulocyte


22,pp. 6737–6747, 2006.

83.R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of




84.Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the treatment of

solid tumors other than melanoma and renal cell carcinoma,” Anti-Cancer

Drugs, vol.17, no.1, pp.1-12, 2006.

85.B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination nonviral

interleukin-2 gene immunotherapy for head and neck cancer: from bench top

to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.

86.A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with perilymphatic

interleukin 2 in patients with resectable squamous cell carcinoma of the oral

cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97, 2002.


87.W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H. Chang,

“Phase I-II study of advanced head and neck squamous cell carcinoma patients

treated with recombinant human interferon gamma,” Archives of


88.S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination cisplatin,

5-fluorouracil, and interferon-alpha in the treatment of advanced esophageal

carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.

89.S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive



2326–2331, 1993.

90.C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral




2635, 2004.

91.J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J. Brandwein,

and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic, induces

maturation and activation of human dendritic cells in vitro,” Journal of


92.M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53 peptide

presented by HLA-A24 induces cytotoxic T lymphocytes that recognize


6, no. 3, pp. 979–986, 2000.

93.T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De Leo,

“p53 as an immunotherapeutic target in head and neck cancer,” Advances in

Otorhinolaryngology, vol. 62, pp. 151–160, 2005.

94.Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune




95.M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-cell

responses to human CEA from patients immunized with recombinant avipox-

CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.

96.J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential





93.Alan M. Krensky; William M. Bennett; Flavio Vincenti. Immunosuppressants,




94.Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.

95.Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller CS



96.Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.



Dermatol. 2002 Feb; 118(2):366-71.

97.Katzung BG. Immunomodulating Agents. In: Basic and Clinical Pharmacology


98.Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology in


99.Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-413.

100. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic

and clinical immunology 6th ed p. 1-14.


102. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34

103. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,

Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of

Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].

104. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].

105. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.

In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,

p.1-49.

106. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial

Series: Rapid Learning Inc:RapidLearningCenter.com.

107. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:


108. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,

and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in


109. Heiserman DL. Immune Response. In: Introduction to Immunology.


/immunology.

110. Ananthnarayan and Panicker. Structure and Functions of the Immune

System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,

2005 [15].

111. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical


112. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,

Immunosuppressants and Immunostimulants. In. Pharmacology and

Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].

113. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.

London, Mosby Elsevier, 2007 [5].

114. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's

Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant

drugs. Churchill Livingstone, Elsevier 2011.

115. Scribed

116. Kat

117. Kat

118. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen

planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.

119. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen

Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,

Issue 3. p289-290.

120. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)

Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].

121. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation

and Management. J. C. D. 68:494-9.

122. Gao F. Determination of corticosteroids in human plasma using

micromass LC/MS/MS. Apr 1, 2003.

123. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.

Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.

124. Shanker

125. L3

126. Aberra NF, Lichtenstein GR. Review Article: Monitoring of

Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.

2005; 21(4):307-319.

127. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in

rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.

1998; 65:267-273.

128. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral

Biology and Medicine 1993; 4(2):141-158.

129. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the

local application of ciclosporine A on chronic erosive lichen planus of the oral

cavity

130. xxx

131. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study

of 570 patients with oral lichen planus: persistence, remission, and malignant


132. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J

Clin Case Rep 3: (2013) 285

133. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.


1977 March 12; 1(6062): 671–674.

134. Irene

135. Ison

136. James SH and David W. Kimberlin DW. Herpes Simplex Virus in

Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.


137. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial

Virus. Drugs R D. 2011 September; 11(3): 215–226.

138. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in



84.




USA, 2008.






100. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck


101. National Comprehensive Cancer Network, Head and Neck Cancers:

National Comprehensive Cancer Network Clinical Practice Guidelines in

Oncology, version 2, November 2008,

http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.

102. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck

cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.

103. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck


104. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV



8942-8949, 2005.

105. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of



no. 12, pp. 1624-1631, 2006.

106. National Institutes of Health. ClinicalTrials.gov, November 2008,


107. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,

a second-generation oncolytic herpes simplex virus expressing granulocyte


22,pp. 6737–6747, 2006.

108. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of




109. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the

treatment of solid tumors other than melanoma and renal cell carcinoma,”

Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.

110. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination

nonviral interleukin-2 gene immunotherapy for head and neck cancer: from

bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.

111. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with

perilymphatic interleukin 2 in patients with resectable squamous cell


carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,

2002.

112. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.

Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma

patients treated with recombinant human interferon gamma,” Archives of


113. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination

cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced

esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.

114. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive



2326–2331, 1993.

115. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral




2635, 2004.

116. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.

Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,

induces maturation and activation of human dendritic cells in vitro,” Journal of


117. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53

peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize


6, no. 3, pp. 979–986, 2000.

118. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De

Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances

in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.

119. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune




120. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-

cell responses to human CEA from patients immunized with recombinant

avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.

121. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential





139. Alan M. Krensky; William M. Bennett; Flavio Vincenti.

Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo

JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of

Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].


141. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller

CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.





Dermatol. 2002 Feb; 118(2):366-71.

143. Katzung BG. Immunomodulating Agents. In: Basic and Clinical

Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].

144. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology

in General Medicine, 7th Edition, 2008 [27].

145. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-

413.











p.1-49.










/immunology.



2005 [15].











161. Scribed

162. Kat

163. Kat





Issue 3. p289-290.









170. Shanker

171. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

176. xxx








1977 March 12; 1(6062): 671–674.

180. Irene

181. Ison









84.

122. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,



USA, 2008.

123. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems

Incorporated, New York, NY, USA, 2008.

124. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head

and neck cancer using tumor antigen-specific monoclonal antibodies,” Current















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.









Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











207. Scribed

208. Kat

209. Kat





Issue 3. p289-290.









216. Shanker

217. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

222. xxx








1977 March 12; 1(6062): 671–674.

226. Irene

227. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.








Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











253. Scribed

254. Kat

255. Kat





Issue 3. p289-290.









262. Shanker

263. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

268. xxx








1977 March 12; 1(6062): 671–674.

272. Irene

273. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.







22,pp. 6737–6747, 2006.














2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.



























Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











299. Scribed

300. Kat

301. Kat





Issue 3. p289-290.









308. Shanker

309. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

314. xxx








1977 March 12; 1(6062): 671–674.

318. Irene

319. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.



























Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











345. Scribed

346. Kat

347. Kat





Issue 3. p289-290.









354. Shanker

355. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

360. xxx








1977 March 12; 1(6062): 671–674.

364. Irene

365. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.









Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











391. Scribed

392. Kat

393. Kat





Issue 3. p289-290.









400. Shanker

401. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

406. xxx








1977 March 12; 1(6062): 671–674.

410. Irene

411. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.








Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











437. Scribed

438. Kat

439. Kat





Issue 3. p289-290.









446. Shanker

447. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

452. xxx








1977 March 12; 1(6062): 671–674.

456. Irene

457. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.







22,pp. 6737–6747, 2006.














2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.



























Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











483. Scribed

484. Kat

485. Kat





Issue 3. p289-290.









492. Shanker

493. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

498. xxx








1977 March 12; 1(6062): 671–674.

502. Irene

503. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.



























Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











529. Scribed

530. Kat

531. Kat





Issue 3. p289-290.









538. Shanker

539. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

544. xxx








1977 March 12; 1(6062): 671–674.

548. Irene

549. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.









Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











575. Scribed

576. Kat

577. Kat





Issue 3. p289-290.









584. Shanker

585. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

590. xxx








1977 March 12; 1(6062): 671–674.

594. Irene

595. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.








Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











621. Scribed

622. Kat

623. Kat





Issue 3. p289-290.









630. Shanker

631. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

636. xxx








1977 March 12; 1(6062): 671–674.

640. Irene

641. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.







22,pp. 6737–6747, 2006.














2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.



























Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











667. Scribed

668. Kat

669. Kat





Issue 3. p289-290.









676. Shanker

677. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

682. xxx








1977 March 12; 1(6062): 671–674.

686. Irene

687. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.



























Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











713. Scribed

714. Kat

715. Kat





Issue 3. p289-290.









722. Shanker

723. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

728. xxx








1977 March 12; 1(6062): 671–674.

732. Irene

733. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.









Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











759. Scribed

760. Kat

761. Kat





Issue 3. p289-290.









768. Shanker

769. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

774. xxx








1977 March 12; 1(6062): 671–674.

778. Irene

779. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.








Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











805. Scribed

806. Kat

807. Kat





Issue 3. p289-290.









814. Shanker

815. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

820. xxx








1977 March 12; 1(6062): 671–674.

824. Irene

825. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.







22,pp. 6737–6747, 2006.














2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.



























Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











851. Scribed

852. Kat

853. Kat





Issue 3. p289-290.









860. Shanker

861. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

866. xxx








1977 March 12; 1(6062): 671–674.

870. Irene

871. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.



























Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











897. Scribed

898. Kat

899. Kat





Issue 3. p289-290.









906. Shanker

907. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

912. xxx








1977 March 12; 1(6062): 671–674.

916. Irene

917. Ison









84.




USA, 2008.



















8942-8949, 2005.




no. 12, pp. 1624-1631, 2006.






22,pp. 6737–6747, 2006.















2002.











2326–2331, 1993.





2635, 2004.








6, no. 3, pp. 979–986, 2000.









Dermatol. 2002 Feb; 118(2):366-71.






413.











p.1-49.










/immunology.



2005 [15].











943. Scribed

944. Kat

945. Kat





Issue 3. p289-290.









952. Shanker

953. L3



2005; 21(4):307-319.



1998; 65:267-273.





cavity

958. xxx








1977 March 12; 1(6062): 671–674.

962. Irene

963. Ison









84.




USA, 2008.



















8942-8949, 2005.


556.

References 2

Documents

Transcript of References 2